Cleared Traditional

K051492 - AESKULISA ASCA A

K051492 is an FDA 510(k) clearance for AESKULISA ASCA A, manufactured by Aesku, Inc.. The device is a Class 2 Immunology device with product code NBT cleared through the Traditional 510(k) pathway after a 161-day FDA review.

K051492 · Aesku, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 2005
Decision
161d
Days
Class 2
Risk

K051492 is an FDA 510(k) clearance for the AESKULISA ASCA A. Classified as Antibodies, Saccharomyces Cerevisiae (s.cerevisiae) (product code NBT), Class II - Special Controls.

Submitted by Aesku, Inc. (Miami, US). The FDA issued a Cleared decision on November 14, 2005 after a review of 161 days - an extended review cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5785 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Immunology review framework, consistent with the majority of Class II 510(k) submissions.

View all Aesku, Inc. devices

FDA 510(k) Submission Details - K051492

510(k) Number K051492 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 06, 2005
Decision Date November 14, 2005
Days to Decision 161 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
56d slower than avg
Panel avg: 105d · This submission: 161d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

NBT Device Classification - Class 2, Special Controls

Product Code NBT Antibodies, Saccharomyces Cerevisiae (s.cerevisiae)
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5785
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - NBT Antibodies, Saccharomyces Cerevisiae (s.cerevisiae)

Devices cleared under the same product code (NBT) and FDA review panel - the closest regulatory comparables to K051492.
TECHLAB ASCA-CHEK
K051927 · Techlab, Inc. · Apr 2006
IMMULISA ANTI-SACCHAROMYCES CEREVISIAE ANTIBODY (ASCA) (IGG)
K032850 · Immco Diagnostics, Inc. · Mar 2004
IMMULISA ANTI-SACCHAROMYCES CEREVISIAE ANTIBODY (ASCA) (IGA)
K032860 · Immco Diagnostics, Inc. · Mar 2004
QUANTA LITE ASCA (S. CEREVISIAE) IGA ELISA
K000733 · Inova Diagnostics, Inc. · May 2001
QUANTA LITE ASCA (S. CEREVISIAE) IGG ELISA
DEN000007 · Inova Diagnostics, Inc. · Aug 2000